Moirai Orthopaedics’ PIR System receives FDA approval to begin clinical studies

Moirai Orthopaedics received approval from the FDA for its investigational device exemption application to initiate a clinical study of its Pyrocarbon Implant Replacement System, according to a News-Medical report.

Advertisement

The PIR System, a single-component implant, is intended for the treatment of articular cartilage defects of the medial femoral condyle. The clinical study will evaluate the safety and efficacy of the device, and it will begin in the summer of 2015. The first implantations will be performed by Deryk Jones, MD, section head of sports medicine at the Ochsner Sports Medicine Institute in New Orleans, according to the report.

 

More articles on devices:
Aurora Spine sales reach $2.5M in 2014 — 10 key notes
5 ratings updates for Smith & Nephew stock
SonicOne OR shows better results for wound issues — 5 things to know

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.